Segall Bryant & Hamill LLC Sells 3,972 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Segall Bryant & Hamill LLC trimmed its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 2.7% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 145,337 shares of the company's stock after selling 3,972 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.50% of Krystal Biotech worth $26,204,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of KRYS. Fifth Third Bancorp boosted its holdings in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after acquiring an additional 105 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Krystal Biotech during the 4th quarter valued at about $95,000. GAMMA Investing LLC boosted its holdings in shares of Krystal Biotech by 179.3% during the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock valued at $121,000 after acquiring an additional 432 shares during the last quarter. Covestor Ltd boosted its holdings in shares of Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after acquiring an additional 642 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of Krystal Biotech during the 1st quarter valued at about $223,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on KRYS. Citigroup reaffirmed a "neutral" rating and set a $176.00 price target (up previously from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. HC Wainwright reiterated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Tuesday, June 24th. Guggenheim lowered their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, Chardan Capital restated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech has an average rating of "Buy" and an average target price of $213.75.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction on Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the completion of the transaction, the insider directly owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 49,800 shares of company stock worth $7,487,943 over the last ninety days. 13.70% of the stock is owned by insiders.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded down $2.27 on Friday, hitting $147.88. 45,620 shares of the company traded hands, compared to its average volume of 286,370. The business has a 50-day simple moving average of $136.27 and a 200 day simple moving average of $156.00. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $219.34. The stock has a market capitalization of $4.27 billion, a P/E ratio of 35.69 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. Research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).